The University of Southampton
University of Southampton Institutional Repository

Safety, efficacy, and immunogenicity of a Salmonella Paratyphi A vaccine

Safety, efficacy, and immunogenicity of a Salmonella Paratyphi A vaccine
Safety, efficacy, and immunogenicity of a Salmonella Paratyphi A vaccine

Background: Salmonellaenterica serovar Paratyphi A (also known as S. Paratyphi A) is responsible for more than 2 million cases of enteric fever annually. There are no licensed vaccines against S. Paratyphi A. 

Methods: in a double-blind, randomized, placebo-controlled trial, we evaluated an orally administered live, attenuated S. Paratyphi A vaccine (CVD 1902) using a controlled human infection model. Healthy U.K. adults were assigned in a 1:1 ratio to receive two doses of CVD 1902 or placebo 14 days apart. Twenty-eight days after the second dose, participants were challenged orally with S. Paratyphi A. The primary end point was a diagnosis of S. Paratyphi A infection within 14 days after challenge. Secondary end points included safety and immunogenicity. 

Results: a total of 72 participants underwent randomization, of whom 34 in the CVD 1902 group and 36 in the placebo group were challenged with S. Paratyphi A. The median age of the participants was 32 years (range, 20 to 54), and 46% were women. The number of adverse events was generally similar in the two groups, and no vaccine-related serious adverse events were identified. CVD 1902 induced serum IgG and IgA responses to the O antigen of S. Paratyphi A. No increases in serum IgG or IgA titers occurred in the placebo group. In the intention-to-treat population, an S. Paratyphi A infection was diagnosed within 14 days after challenge in 21% of the participants in the CVD 1902 group and in 75% of those in the placebo group (P<0.001), resulting in a vaccine efficacy of 73% (95% confidence interval [CI], 46 to 86). The vaccine efficacy was 69% (95% CI, 42 to 84) in the per-protocol analysis. 

Conclusions: in healthy U.K. adults who were challenged with S. Paratyphi A in a controlled human infection model, a two-dose series of CVD 1902 led to protection against S. Paratyphi A infection without safety concerns.

Bacterial Infections, Global Health, Infectious Disease, Infectious Disease General, Vaccines
0028-4793
1704-1714
McCann, Naina
5cda7cdb-78a3-41e7-b32f-1ae0cb0c53c4
Vicentine, Margarete Paganotti
3127eb1f-7c24-463d-80e4-113bc3b84368
Ebrahimi, Narges
f9a077b3-ebf4-4cde-81e4-52650cf25983
Greenland, Melanie
f1ad44ed-4d20-4800-9d91-89a103a46182
Angus, Brian
24f9d013-2967-4282-81b0-23d4528d49fd
Collins, Andrea M.
7c571856-429e-48f9-9e72-d70911ac9509
Darton, Thomas
563cb98c-d30e-49d6-b71e-b291afa586db
Emary, Katherine
dd588fbe-d37a-44ac-a5f6-5f44c48fbfd5
Faust, Saul N.
f97df780-9f9b-418e-b349-7adf63e150c1
Flaxman, Amy
1227d180-aaca-4958-bb5a-d6fd5e788c21
Maria, Noshi
b0b9da3c-bbfa-4dfe-987d-7fe2ca4408e1
Green, Christopher A.
4940709e-a083-44ae-812a-60af3c468811
Molina, Claudia Juarez
3e123c11-58e8-4928-9492-a43a4d72ab4f
Paidisetti, Ravindra
df44801c-537d-41b5-ba85-d7d2ea23a898
Lazarus, Rajeka
9cef06db-d282-42b9-85fe-5ae26bdf6813
Macaulay, Grace C.
a56c73ac-fab1-4b72-873c-2829f10a39cf
McLean, Florence
6652a87b-6892-49a9-b181-4c3ea675e9be
Mohan, V. Krishna
c1783c97-5e5d-4ab0-97e7-62dacddfaa28
Naidu, M. Gangadhara
2ae99d63-6163-4f0e-9a4c-3524b4e8d92d
Ramasamy, Maheshi N.
ae42fa67-f3e2-430a-81da-92d601b96b79
Rao, D. Yogeswara
215a3944-15e1-4f68-82d8-dc2604c81dec
Singh, Nisha
6efdfb3b-0148-4874-94eb-b8440c9922eb
Vernon, Sophie
65901690-5d37-4df3-b990-b060f8edc3fe
Kim, Young Chan
ce52e423-13b2-4b5e-aea1-36ede5e76078
Levine, Myron M.
0596c5bc-2165-45f7-917f-90b53ee9fb54
Liu, Xinxue
9167ef53-49a2-4100-a050-87569421468f
Pollard, Andrew J.
3057c98b-3868-4bbb-a69f-f4660c2afd93
VASP Study Team
McCann, Naina
5cda7cdb-78a3-41e7-b32f-1ae0cb0c53c4
Vicentine, Margarete Paganotti
3127eb1f-7c24-463d-80e4-113bc3b84368
Ebrahimi, Narges
f9a077b3-ebf4-4cde-81e4-52650cf25983
Greenland, Melanie
f1ad44ed-4d20-4800-9d91-89a103a46182
Angus, Brian
24f9d013-2967-4282-81b0-23d4528d49fd
Collins, Andrea M.
7c571856-429e-48f9-9e72-d70911ac9509
Darton, Thomas
563cb98c-d30e-49d6-b71e-b291afa586db
Emary, Katherine
dd588fbe-d37a-44ac-a5f6-5f44c48fbfd5
Faust, Saul N.
f97df780-9f9b-418e-b349-7adf63e150c1
Flaxman, Amy
1227d180-aaca-4958-bb5a-d6fd5e788c21
Maria, Noshi
b0b9da3c-bbfa-4dfe-987d-7fe2ca4408e1
Green, Christopher A.
4940709e-a083-44ae-812a-60af3c468811
Molina, Claudia Juarez
3e123c11-58e8-4928-9492-a43a4d72ab4f
Paidisetti, Ravindra
df44801c-537d-41b5-ba85-d7d2ea23a898
Lazarus, Rajeka
9cef06db-d282-42b9-85fe-5ae26bdf6813
Macaulay, Grace C.
a56c73ac-fab1-4b72-873c-2829f10a39cf
McLean, Florence
6652a87b-6892-49a9-b181-4c3ea675e9be
Mohan, V. Krishna
c1783c97-5e5d-4ab0-97e7-62dacddfaa28
Naidu, M. Gangadhara
2ae99d63-6163-4f0e-9a4c-3524b4e8d92d
Ramasamy, Maheshi N.
ae42fa67-f3e2-430a-81da-92d601b96b79
Rao, D. Yogeswara
215a3944-15e1-4f68-82d8-dc2604c81dec
Singh, Nisha
6efdfb3b-0148-4874-94eb-b8440c9922eb
Vernon, Sophie
65901690-5d37-4df3-b990-b060f8edc3fe
Kim, Young Chan
ce52e423-13b2-4b5e-aea1-36ede5e76078
Levine, Myron M.
0596c5bc-2165-45f7-917f-90b53ee9fb54
Liu, Xinxue
9167ef53-49a2-4100-a050-87569421468f
Pollard, Andrew J.
3057c98b-3868-4bbb-a69f-f4660c2afd93

McCann, Naina, Vicentine, Margarete Paganotti and Ebrahimi, Narges , VASP Study Team (2025) Safety, efficacy, and immunogenicity of a Salmonella Paratyphi A vaccine. New England Journal of Medicine, 393 (17), 1704-1714. (doi:10.1056/NEJMoa2502992).

Record type: Article

Abstract

Background: Salmonellaenterica serovar Paratyphi A (also known as S. Paratyphi A) is responsible for more than 2 million cases of enteric fever annually. There are no licensed vaccines against S. Paratyphi A. 

Methods: in a double-blind, randomized, placebo-controlled trial, we evaluated an orally administered live, attenuated S. Paratyphi A vaccine (CVD 1902) using a controlled human infection model. Healthy U.K. adults were assigned in a 1:1 ratio to receive two doses of CVD 1902 or placebo 14 days apart. Twenty-eight days after the second dose, participants were challenged orally with S. Paratyphi A. The primary end point was a diagnosis of S. Paratyphi A infection within 14 days after challenge. Secondary end points included safety and immunogenicity. 

Results: a total of 72 participants underwent randomization, of whom 34 in the CVD 1902 group and 36 in the placebo group were challenged with S. Paratyphi A. The median age of the participants was 32 years (range, 20 to 54), and 46% were women. The number of adverse events was generally similar in the two groups, and no vaccine-related serious adverse events were identified. CVD 1902 induced serum IgG and IgA responses to the O antigen of S. Paratyphi A. No increases in serum IgG or IgA titers occurred in the placebo group. In the intention-to-treat population, an S. Paratyphi A infection was diagnosed within 14 days after challenge in 21% of the participants in the CVD 1902 group and in 75% of those in the placebo group (P<0.001), resulting in a vaccine efficacy of 73% (95% confidence interval [CI], 46 to 86). The vaccine efficacy was 69% (95% CI, 42 to 84) in the per-protocol analysis. 

Conclusions: in healthy U.K. adults who were challenged with S. Paratyphi A in a controlled human infection model, a two-dose series of CVD 1902 led to protection against S. Paratyphi A infection without safety concerns.

Text
VASP_manuscript_NEJM_final_wordversion - Accepted Manuscript
Download (901kB)
Text
VASP_manuscript_NEJM_final_wordversion
Restricted to Repository staff only
Request a copy

More information

e-pub ahead of print date: 29 October 2025
Published date: 30 October 2025
Keywords: Bacterial Infections, Global Health, Infectious Disease, Infectious Disease General, Vaccines

Identifiers

Local EPrints ID: 508627
URI: http://eprints.soton.ac.uk/id/eprint/508627
ISSN: 0028-4793
PURE UUID: 0b191ac5-ddb9-4a2a-8704-26b2871b71a0
ORCID for Saul N. Faust: ORCID iD orcid.org/0000-0003-3410-7642

Catalogue record

Date deposited: 28 Jan 2026 17:49
Last modified: 29 Jan 2026 03:13

Export record

Altmetrics

Contributors

Author: Naina McCann
Author: Margarete Paganotti Vicentine
Author: Narges Ebrahimi
Author: Melanie Greenland
Author: Brian Angus
Author: Andrea M. Collins
Author: Thomas Darton
Author: Katherine Emary
Author: Saul N. Faust ORCID iD
Author: Amy Flaxman
Author: Noshi Maria
Author: Christopher A. Green
Author: Claudia Juarez Molina
Author: Ravindra Paidisetti
Author: Rajeka Lazarus
Author: Grace C. Macaulay
Author: Florence McLean
Author: V. Krishna Mohan
Author: M. Gangadhara Naidu
Author: Maheshi N. Ramasamy
Author: D. Yogeswara Rao
Author: Nisha Singh
Author: Sophie Vernon
Author: Young Chan Kim
Author: Myron M. Levine
Author: Xinxue Liu
Author: Andrew J. Pollard
Corporate Author: VASP Study Team

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×